Harvey V - Search Results

1

Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer.

Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M, Cold S. Harvey V, et al. J Clin Oncol. 2006 Nov 1;24(31):4963-70. doi: 10.1200/JCO.2005.05.0294. Epub 2006 Oct 10. J Clin Oncol. 2006. PMID: 17033039 Clinical Trial.

2

Effective salvage chemotherapy with etoposide, dactinomycin, and methotrexate in refractory germ cell cancer. Australasian Germ Cell Trial Group.

Levi JA, Thomson D, Harvey V, Gill G, Raghavan D, Tattersall M, Snyder R, Burns I, Sandeman T, Byrne M, et al. Levi JA, et al. Among authors: harvey v. J Clin Oncol. 1990 Jan;8(1):27-32. doi: 10.1200/JCO.1990.8.1.27. J Clin Oncol. 1990. PMID: 2153192

3

A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up.

Levi JA, Thomson D, Sandeman T, Tattersall M, Raghavan D, Byrne M, Gill G, Harvey V, Burns I, Snyder R. Levi JA, et al. Among authors: harvey v. J Clin Oncol. 1988 Jul;6(7):1154-60. doi: 10.1200/JCO.1988.6.7.1154. J Clin Oncol. 1988. PMID: 2455778 Clinical Trial.

4

The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group.

Levi JA, Raghavan D, Harvey V, Thompson D, Sandeman T, Gill G, Stuart-Harris R, Snyder R, Byrne M, Kerestes Z, et al. Levi JA, et al. Among authors: harvey v. J Clin Oncol. 1993 Jul;11(7):1300-5. doi: 10.1200/JCO.1993.11.7.1300. J Clin Oncol. 1993. PMID: 7686216 Clinical Trial.

5

Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer.

Holdaway IM, Mason BH, Lethaby AE, Singh V, Harvey VJ, Thompson PI, Evans BD. Holdaway IM, et al. Among authors: harvey vj. ANZ J Surg. 2003 Nov;73(11):905-8. doi: 10.1046/j.1445-2197.2003.02817.x. ANZ J Surg. 2003. PMID: 14616567

6

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. Baselga J, et al. Among authors: harvey v. J Clin Oncol. 2005 Apr 1;23(10):2162-71. doi: 10.1200/JCO.2005.01.014. J Clin Oncol. 2005. PMID: 15800309 Clinical Trial.

7

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98. Viale G, et al. J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3. J Clin Oncol. 2008. PMID: 18981464 Free PMC article. Clinical Trial.

8

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

Green MD, Francis PA, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Fong A, Basser R, Forbes JF; Australian New Zealand Breast Cancer Trials Group. Green MD, et al. Among authors: harvey v. Ann Oncol. 2009 Nov;20(11):1813-7. doi: 10.1093/annonc/mdp202. Epub 2009 Jun 24. Ann Oncol. 2009. PMID: 19553291 Free article. Clinical Trial.

9

Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS. Stockler MR, et al. Among authors: harvey vj. J Clin Oncol. 2011 Dec 1;29(34):4498-504. doi: 10.1200/JCO.2010.33.9101. Epub 2011 Oct 24. J Clin Oncol. 2011. PMID: 22025143 Clinical Trial.

10

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee. Mieog JS, et al. Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20. Lancet Oncol. 2012. PMID: 22265698 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters